Investigational Tango–Revolution Drug Combination Shows Encouraging Early Activity in Pancreatic Cancer

Early Clinical Results Highlight Potential New Treatment Strategy As reported on STAT News, a novel investigational drug combination developed through a collaboration between Tango Therapeutics and Revolution Medicines has demonstrated…

Continue Reading Investigational Tango–Revolution Drug Combination Shows Encouraging Early Activity in Pancreatic Cancer

Opdivo–Cabometyx Combination Shows Significant Survival Benefit in Advanced Kidney Cancer

As reported on Yahoo News, a combination therapy involving nivolumab (Opdivo) from Bristol Myers Squibb and cabozantinib (Cabometyx) from Exelixis has demonstrated substantial clinical benefit in patients with previously untreated…

Continue Reading Opdivo–Cabometyx Combination Shows Significant Survival Benefit in Advanced Kidney Cancer

FDA Approves Pembrolizumab–Belzutifan Combination for Adjuvant Treatment of High-Risk Clear Cell RCC

As reported on Pharmaceutical Technology, the US Food and Drug Administration (FDA) has approved a new adjuvant treatment option for adults with clear cell renal cell carcinoma (ccRCC) at elevated…

Continue Reading FDA Approves Pembrolizumab–Belzutifan Combination for Adjuvant Treatment of High-Risk Clear Cell RCC